191 related articles for article (PubMed ID: 33896096)
1. Prolonged Response to HER2-Directed Therapy in Three Patients with HER2-Amplified Metastatic Carcinoma of the Biliary System: Case Study and Review of the Literature.
May M; Raufi AG; Sadeghi S; Chen K; Iuga A; Sun Y; Ahmed F; Bates S; Manji GA
Oncologist; 2021 Aug; 26(8):640-646. PubMed ID: 33896096
[TBL] [Abstract][Full Text] [Related]
2. HER2/neu-directed therapy for biliary tract cancer.
Javle M; Churi C; Kang HC; Shroff R; Janku F; Surapaneni R; Zuo M; Barrera C; Alshamsi H; Krishnan S; Mishra L; Wolff RA; Kaseb AO; Thomas MB; Siegel AB
J Hematol Oncol; 2015 May; 8():58. PubMed ID: 26022204
[TBL] [Abstract][Full Text] [Related]
3. Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer.
Hiraoka N; Nitta H; Ohba A; Yoshida H; Morizane C; Okusaka T; Nara S; Esaki M; Kishi Y; Shimada K
Hum Pathol; 2020 Nov; 105():9-19. PubMed ID: 32891647
[TBL] [Abstract][Full Text] [Related]
4. HER2 testing in gastric cancer.
Albarello L; Pecciarini L; Doglioni C
Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
[TBL] [Abstract][Full Text] [Related]
5. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
Hechtman JF; Polydorides AD
Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
[TBL] [Abstract][Full Text] [Related]
6. Pertuzumab in gastrointestinal cancer.
Oh DY; Bang YJ
Expert Opin Biol Ther; 2016; 16(2):243-53. PubMed ID: 26619359
[TBL] [Abstract][Full Text] [Related]
7. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
Meric-Bernstam F; Johnson AM; Dumbrava EEI; Raghav K; Balaji K; Bhatt M; Murthy RK; Rodon J; Piha-Paul SA
Clin Cancer Res; 2019 Apr; 25(7):2033-2041. PubMed ID: 30442682
[TBL] [Abstract][Full Text] [Related]
8. HER2 gene (ERBB2) amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma.
Albrecht T; Rausch M; Roessler S; Geissler V; Albrecht M; Halske C; Seifert C; Renner M; Singer S; Mehrabi A; Vogel MN; Pathil-Warth A; Busch E; Köhler B; Rupp C; Weiss KH; Springfeld C; Röcken C; Schirmacher P; Goeppert B
Virchows Arch; 2020 Jun; 476(6):871-880. PubMed ID: 31838585
[TBL] [Abstract][Full Text] [Related]
9. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
Galdy S; Lamarca A; McNamara MG; Hubner RA; Cella CA; Fazio N; Valle JW
Cancer Metastasis Rev; 2017 Mar; 36(1):141-157. PubMed ID: 27981460
[TBL] [Abstract][Full Text] [Related]
10. Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas.
Augustin J; Gabignon C; Scriva A; Menu L; Calmel C; Scatton O; Paye F; Fléjou JF; Praz F; Cervera P; Wendum D
Virchows Arch; 2020 Jul; 477(1):33-45. PubMed ID: 32447492
[TBL] [Abstract][Full Text] [Related]
11. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.
Liang Z; Zeng X; Gao J; Wu S; Wang P; Shi X; Zhang J; Liu T
BMC Cancer; 2008 Dec; 8():363. PubMed ID: 19061514
[TBL] [Abstract][Full Text] [Related]
12. Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.
Kawamoto T; Ishige K; Thomas M; Yamashita-Kashima Y; Shu S; Ishikura N; Ariizumi S; Yamamoto M; Kurosaki K; Shoda J
J Gastroenterol; 2015 Apr; 50(4):467-79. PubMed ID: 25112701
[TBL] [Abstract][Full Text] [Related]
13. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.
Javle M; Borad MJ; Azad NS; Kurzrock R; Abou-Alfa GK; George B; Hainsworth J; Meric-Bernstam F; Swanton C; Sweeney CJ; Friedman CF; Bose R; Spigel DR; Wang Y; Levy J; Schulze K; Cuchelkar V; Patel A; Burris H
Lancet Oncol; 2021 Sep; 22(9):1290-1300. PubMed ID: 34339623
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significance of HER2 positivity in gallbladder adenocarcinoma].
Yao JG; Wang CH; Liu Y
Zhonghua Bing Li Xue Za Zhi; 2017 Apr; 46(4):245-248. PubMed ID: 28376590
[No Abstract] [Full Text] [Related]
15. A survival guide to HER2 testing in gastric/gastroesophageal junction carcinoma.
Subasinghe D; Acott N; Kumarasinghe MP
Gastrointest Endosc; 2019 Jul; 90(1):44-54. PubMed ID: 30928424
[TBL] [Abstract][Full Text] [Related]
16. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
[TBL] [Abstract][Full Text] [Related]
17. ISH-based HER2 diagnostics.
Rüschoff J; Nagelmeier I; Jasani B; Stoss O
Pathologe; 2021 Nov; 42(Suppl 1):62-68. PubMed ID: 33346874
[TBL] [Abstract][Full Text] [Related]
18. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
[TBL] [Abstract][Full Text] [Related]
19. [Amplification of HER2 gene in gastric carcinoma detected by dual in-situ hybridization].
Sin LF; Vong HT; Wen JM; Yip YC
Zhonghua Bing Li Xue Za Zhi; 2012 Mar; 41(3):168-71. PubMed ID: 22800479
[TBL] [Abstract][Full Text] [Related]
20. Targeting ERBB2/HER2 genetic alterations: an expanding therapeutic opportunity in gastrointestinal cancers.
Zheng-Lin B; Graham RP; Bekaii-Saab TS
Chin Clin Oncol; 2023 Oct; 12(5):55. PubMed ID: 37964543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
